NeoCart
-
Hospitals
Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway
WALTHAM, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More » -
Biologics
Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More » -
Hospitals
Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
WALTHAM, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More » -
Biologics
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage
WALTHAM, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative…
Read More » -
Biologics
Histogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market
WALTHAM, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell…
Read More » -
Biologics
Histogenics Agreement With Japan Pharmaceuticals and Medical Devices Agency and Regulatory Pathway for NeoCart®
WALTHAM, Mass., May 08, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Sports Medicine
Histogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine
WALTHAM, Mass., Jan. 11, 2017 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (HSGX), a regenerative medicine company focused on developing and…
Read More » -
Financial
Histogenics Corporation Acquires NeoCart® Development and Commercialization Rights for Japanese Market
WALTHAM, Mass., May 10, 2016 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Hospitals
Histogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria
WALTHAM, Mass., Dec. 21, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More » -
Biologics
Histogenics Corporation and Collagen Solutions plc Establish Supply Agreement
WALTHAM, Mass., Sept. 16, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing…
Read More » -
Spine
Histogenics Corporation Announces World Class Scientific Advisory Board to Support Commercialization and Pipeline Development
WALTHAM, Mass., May 11, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More »